GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Biotechnology Corp (ROCO:3176) » Definitions » Short Interest

Medigen Biotechnology (ROCO:3176) Short Interest


View and export this data going back to 2011. Start your Free Trial

What is Medigen Biotechnology Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Medigen Biotechnology's Short Interest

For the Biotechnology subindustry, Medigen Biotechnology's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medigen Biotechnology's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's Short Interest distribution charts can be found below:

* The bar in red indicates where Medigen Biotechnology's Short Interest falls into.


Medigen Biotechnology (ROCO:3176) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Biotechnology Corp (ROCO:3176) » Definitions » Short Interest
Comparable Companies
ROCO:6838 ROCO:06891 ROCO:4726 ROCO:4167 ROCO:6676 TPE:1734 TPE:6657 ROCO:6885 ROCO:6492 ROCO:6634 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Website
https://www.medigen.com.tw
Medigen Biotechnology Corp is a biopharmaceutical company primarily engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The new drug development business focuses mainly on the clinical stage of drug development and includes PI-88 MUPAFOSTAT for the treatment of liver cancer and OBP-301 treatment using adenovirus targeted to cancer cells only. Drug discovery includes the development of human-native mAbs for therapeutic applications related to infectious diseases. Generic drugs include pharmaceuticals for infectious diseases (antibiotics), contraceptives, nutrition milk powder, vitamin C tablets, dermatologic agents, and eye care products.

Medigen Biotechnology (ROCO:3176) Headlines

No Headlines